1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Lee's Pharmaceutical Holdings Limited
  6. News
  7. Summary
    950   KYG5438W1116

LEE'S PHARMACEUTICAL HOLDINGS LIMITED

(950)
  Report
Delayed Hong Kong Stock Exchange  -  05/17 04:08:55 am EDT
1.910 HKD    0.00%
12:03pSorrento Therapeutics License Partner Completes Enrollment in Small-Cell Lung Cancer Treatment Trial
MT
04/22Lee's Pharmaceutical Secures Chinese Regulatory Approval for Respiratory Drug
MT
03/29Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Lee Pharmaceutical : VOLUNTARY ANNOUNCEMENT - UPDATE ON THE INTRODUCTION AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ANTICOAGULANT

08/29/2018 | 10:37am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT -

UPDATE ON THE INTRODUCTION AND RESEARCH AND

DEVELOPMENT OF

AN INVESTIGATIONAL ANTICOAGULANT

This announcement is made by the board of directors (the "Board") of Lee's Pharmaceutical Holdings Limited (the "Company", together with its subsidiaries as the "Group") on a voluntary basis.

The Board of the Company is pleased to announce that, on 14 June 2018, the Group has been granted approval from the China National Drug Administration ("CNDA") to conduct clinical trials investigating Tecarfarin as a potential treatment for patients with mechanical heart valves. Tecarfarin will be studied as a possible alternative to Warfarin.

Tecarfarin was licensed by the Group from Espero BioPharma, Inc. ("Espero") in 2015.

The Group has successfully completed the technology transfer for drug substance and product in China. An open-label, Phase I, sequential cohort, single-dose escalation study will be initiated by the end of this year to access the safety and tolerability of Tecarfarin in healthy Chinese volunteers. Following a Phase I study in China, the Group will initiate a Phase III registration enabling study. Tecarfarin will be manufactured in the manufacturing site of the Group in Nansha, PRC.

Many patients who have undergone heart valve replacement also have indications for anti-coagulation. In the case of patients with prosthetic heart valves, the presence of a foreign material can stimulate a clotting response. Patients with mechanical heart valves require chronic anti-coagulation. There have been more than 200,000 cases of cardiac valve replacement surgeries in China and 98% of patients received mechanical heart valves (Chen, Q., Dong, L., Dong, Y. et al. J Cardiothorac Surg, 2015). These patients are younger and they must adhere to life-long anticoagulation therapy for which Warfarin is widely prescribed. Tecarfarin may be a suitable alternative for these patientsas well, due to the known drug-drug interactions between Warfarin and other atrial fibrillation (AFib) medications. Tecarfarin also provides a potential alternative to patient populations as direct thrombin inhibitors and Factor Xa inhibitors are contraindicated for use in individuals with mechanical heart valves and post myocardial infarction.

Tecarfarin may potentially improve stability in maintaining a therapeutic anti-coagulation level. This investigational therapy may offer potential for treatment in patients with mechanical and prosthetic heart valves, as well as those with renal dysfunction. It may also present advantages over novel oral anti-coagulants that contain direct thrombin inhibitors and Factor Xa inhibitors, because as a Vitamin K Antagonist, Tecarfarin potentially maintains the ability to be counteracted in the event of an emergency.

The Group is currently a market leader in anti-thrombotic area in China, including Livaracine, its proprietary low molecular weight heparin. It has a robust pipeline of anti-thrombotic, such as a Phase III Warfarin like anticoagulant, Tecarfarin, a Phase II anti-platelet drug, Anfibatide, a Phase I oral Factor Xa inhibitor anticoagulant, GCC-4401C and a synthetic anti-thrombotic agent, Fondaparinux.

The Group is fully integrated with solid infrastructures in drug development, clinic, perspectives and currently markets 17 products in the PRC. Lee's Pharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. It has more than 50 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies.

By order of the Board of

Lee's Pharmaceutical Holdings Limited

Lee Siu Fong

Chairman

Hong Kong, 29 August 2018

*

For identification purpose only

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.

Disclaimer

Lee's Pharmaceutical Holdings Limited published this content on 29 August 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 29 August 2018 14:36:02 UTC


ę Publicnow 2018
All news about LEE'S PHARMACEUTICAL HOLDINGS LIMITED
12:03pSorrento Therapeutics License Partner Completes Enrollment in Small-Cell Lung Cancer Tr..
MT
04/22Lee's Pharmaceutical Secures Chinese Regulatory Approval for Respiratory Drug
MT
03/29Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 Dec..
CI
03/29Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended ..
CI
01/02Lee's Pharmaceutical Holdings Limited Announces Management Appointments
CI
2021Listing on Guidance for Family Choice Pharmacy of Lee's Pharm signature products, Ferpl..
AQ
2021Lee's Pharma's Q3 Profit Plunges 45% Despite Revenue Hike
MT
2021Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Third Quarter an..
CI
2021Lee's Pharmaceutical Arm Enrolls First Patient in Clinical Trial of Melanoma Treatment ..
MT
2021Sorrento License Partner Files China New Drug Application for Socazolimab Cervical Canc..
MT
More news
Financials
Sales 2022 1 465 M 187 M 187 M
Net income 2022 - - -
Net cash 2022 1 829 M 233 M 233 M
P/E ratio 2022 -
Yield 2022 2,51%
Capitalization 1 125 M 143 M 143 M
EV / Sales 2022 -0,48x
EV / Sales 2023 -0,48x
Nbr of Employees 1 319
Free-Float 37,9%
Chart LEE'S PHARMACEUTICAL HOLDINGS LIMITED
Duration : Period :
Lee's Pharmaceutical Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEE'S PHARMACEUTICAL HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,91 HKD
Average target price 4,85 HKD
Spread / Average Target 154%
Managers and Directors
Wanee Leelalertsuphakun MD, Executive Director, CMO & Chief Sales Officer
Yiu Ming Chow Chief Financial Officer & Secretary
Siu Fong Lee Chairman
Yuanjue Sun Chief Medical Officer
Yueshen Chen Administration Director
Sector and Competitors
1st jan.Capi. (M$)
LEE'S PHARMACEUTICAL HOLDINGS LIMITED-42.64%143
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ELI LILLY AND COMPANY8.38%269 490
ROCHE HOLDING AG-14.96%260 807